Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions |
umls-concept:C0014467,
umls-concept:C0019588,
umls-concept:C0021469,
umls-concept:C0030685,
umls-concept:C0032172,
umls-concept:C0055147,
umls-concept:C0086418,
umls-concept:C0271510,
umls-concept:C0391871,
umls-concept:C0442027,
umls-concept:C0680255,
umls-concept:C1123023,
umls-concept:C1280500,
umls-concept:C1283071,
umls-concept:C1515655,
umls-concept:C1963578
|
pubmed:issue |
1
|
pubmed:dateCreated |
1988-8-18
|
pubmed:abstractText |
The use of a noninvasive skin chamber technique in vivo in pollen-sensitive patients allowed us to quantify the time-course release of histamine and the recruitment of inflammatory cells (i.e., neutrophils, monocytes, and eosinophils) in skin sites challenged with pollen, histamine, and compound 48/80. The new H1-receptor antagonist, cetirizine 2 HCl, orally administered with 10 mg once a day to pollen-sensitive patients in a double-blind, crossover study versus placebo, induced a significant decrease in the wheal-and-flare cutaneous reaction induced by intradermal injection of pollen, histamine, and compound 48/80. It also significantly inhibited the immediate histamine release occurring in skin chambers after pollen introduction, whereas it did not significantly inhibit the late release. In patients receiving placebo, we detected platelet-activating factor-acether in media collected at the sixth hour from chambers filled with pollen. With cetirizine 2 HCl treatment, platelet-activating factor-acether was not detected in chamber media. Interestingly, cetirizine 2 HCl significantly reduced the eosinophil recruitment observed on the superficial dermis 24 hours after pollen challenge.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Cetirizine,
http://linkedlifedata.com/resource/pubmed/chemical/Histamine,
http://linkedlifedata.com/resource/pubmed/chemical/Histamine H1 Antagonists,
http://linkedlifedata.com/resource/pubmed/chemical/Hydroxyzine,
http://linkedlifedata.com/resource/pubmed/chemical/Platelet Activating Factor
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
0091-6749
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
82
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
101-9
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:2899102-Administration, Oral,
pubmed-meshheading:2899102-Adolescent,
pubmed-meshheading:2899102-Adult,
pubmed-meshheading:2899102-Cetirizine,
pubmed-meshheading:2899102-Eosinophils,
pubmed-meshheading:2899102-Female,
pubmed-meshheading:2899102-Histamine,
pubmed-meshheading:2899102-Histamine H1 Antagonists,
pubmed-meshheading:2899102-Humans,
pubmed-meshheading:2899102-Hydroxyzine,
pubmed-meshheading:2899102-Hypersensitivity, Immediate,
pubmed-meshheading:2899102-Male,
pubmed-meshheading:2899102-Platelet Activating Factor,
pubmed-meshheading:2899102-Skin
|
pubmed:year |
1988
|
pubmed:articleTitle |
Inhibitory effect of oral cetirizine on in vivo antigen-induced histamine and PAF-acether release and eosinophil recruitment in human skin.
|
pubmed:affiliation |
Unité INSERM U 312, Service de Dermatologie, Hôpital Henri Mondor, Creteil, France.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Controlled Clinical Trial,
Research Support, Non-U.S. Gov't
|